supported by the National Key R&D Program of China(2019YFA0906100 and 2019YFA0904200 to Y.J.C.);the Shenzhen Science and Technology Innovation Program(JCYJ20180504165501371 to Y.J.C.);the National Natural Science Foundation of China(32171464 and 81872783 to Y.J.C.),the Prevention and Control of COVID-2019 Research Program in University of Guangdong Province(2020KZDZX1176 to S.Z.);the Shenzhen Basic Research Program(JCYJ20180507182203049 to S.Z.);the Shenzhen Key Laboratory Foundation(ZDSYS20200811143757022 to S.Z.).
Dear Editor,Chimeric antigen receptor T(CAR-T)cells have achieved substantial advances in the treatment of B-cell malignancies.Despite high initial response rates,some patients relapse,characterized by targeted antige...